WO2008071684A2 - Spezialextrakt und seine verwendung zur hemmung des abbaus von cyclischem guanosinmonophosphat (cgmp) - Google Patents
Spezialextrakt und seine verwendung zur hemmung des abbaus von cyclischem guanosinmonophosphat (cgmp) Download PDFInfo
- Publication number
- WO2008071684A2 WO2008071684A2 PCT/EP2007/063668 EP2007063668W WO2008071684A2 WO 2008071684 A2 WO2008071684 A2 WO 2008071684A2 EP 2007063668 W EP2007063668 W EP 2007063668W WO 2008071684 A2 WO2008071684 A2 WO 2008071684A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- turnera
- extract
- preparation
- var
- parts
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
Definitions
- the following invention relates to a process for the preparation of extracts of a plant from the family Turneraceae, the extracts thus obtained and their use.
- the WHO defines the human right in terms of sexuality and others. as a right to the highest achievable standard of sexual health, and to be able to lead a satisfying, safe, and enjoyable sex life. (WHO Progress in Reproductive Health Research 2004, No. 67, pp. 3).
- the penis contains the dorsolateral corpora corpora cervenosa, as well as the medioventral corpus corpus spongiosum, which are spongy structures of cavernous spaces. These cavernous spaces are lined with vascular epithelial cells and pass over the arteria pudenda interna supplied with blood. About the vena dorsalis penis profunda the blood drains off again.
- Erection and detuning are hemodynamic processes that are regulated by relaxation and contraction of the cavernous musculature.
- nitric oxide acts as an "endothelium-derived relaxing factor.” It diffuses into the smooth muscle cells and activates guanylate cyclase, inducing the formation of cGMP from GTP.
- CGMP leads to a relaxation of the smooth muscle of the corpus cavernosum. V) to guanosine monophosphate (GMP) and thus inactivated (Chew et al., Med. J. Aust. 172, 279-283, 2000).
- sildenafil among other things, reduced blood pressure, headache, dyspepsia and muscle pain (Source: http://www.medhost.de/impotenz/sildenafil.html).
- Herbal preparations are known to have a very low spectrum of side effects.
- search for aphrodisiacs from nature one quickly arrives at a large number of sometimes obscure "remedies", which have often been used for centuries.
- a limited to vegetable preparations viewing the subject still results in almost all primitives to a variety of plants and used preparationsutzster qualities and potencies (plant powder, tea 's, decoctions, liquid extracts).
- the object of the present invention was to find a plant which is active with respect to ED and to convert its active constituents into a reproducible extract form. Thus, a therapeutically uniform and effective dose is to be ensured.
- the shape of a highly concentrated plant extract is particularly suitable compared to the original plant part.
- a pharmacological in vitro screening traditionally aphrodisiac plants were examined for potential PDE-V inhibition. In this case, an active plant family was discovered, the saffron mallow family (Turneraceae).
- a plant of this genus, the Turnera diffusa, German name Damiana, is native to the Gulf of Mexico and the Caribbean. Traditionally, the dried leaves of Turnera diffusa and its varieties the strengthening of the sex drive in the form of drug powder, tea 's or tonic are consumed.
- the object is achieved by the inventive method for producing the extracts.
- the invention therefore firstly a method for producing an extract of a plant from the family Turneraceae comprising the steps
- Turneraceae are suitable as starting plants, in particular Turnera acaulis, Turnera acuta, Turnera alba, Turnera albicans, Turnera amapaensis, Turnera angustifolia, Turnera annectens, Turnera annularis, Turnera annularis var.
- Turnera caroliniana Turnera carpinifolia, Turnera castilloi, Turnera chamaedrifolie, Turnera chamaedrys, Turnera chrysocephala, Turnera chrysodo-xa, Turnera cicatricosa, Turnera cipoensis, Turnera cistoides, Turnera clausenia-na, Turnera coerulea, Turnera collotricha, Turnera concinna, Turnera corchorifolia, Turnera corchoroides, Turnera coriacea, Turnera crulsii, Turnera cuneifolia, Turnera cu- Neiformis, Turnera curassavica, Turnera dasystyla, Turnera dasytricha, Turnera decipiens, Turnera desvauxii, Turnera dichotoma, Turnera dichotoma var.
- Turnera hilaireana var. oblongifo-lia, Turnera hilaireana var. ovatifolia Turnera hindsiana, Turnera hindsiana subsp.
- Lycopifolia Turnera poh-liana, Turnera prancei, Turnera princeps, Turnera pringlei, Turnera procumbens, Turnera pumila, Turnera pumilea, Turnera pumilea var.
- Piauhyensis Turnera pumileoides, Turnera purpurascens, Turnera racemosa, Turnera ramosissima, Turnera refracta, Turnera revoluta, Turnera riedeliana, Turnera rosea, Turnera rubrobracteata, Turnera rugosa, Turnera rupestris, Turnera rupestris var.
- holo-sericea Turnera sidoides subsp. integrifolia, Turnera sidoides subsp. pinnatifida, Turnera sidoides var. angustiloba, Turnera sidoides var. grisebachiana, Turnera sidoides var. herteriana, Turnera sidoides var. hispida, Turnera sidoides var. holosericea, Turnera sidoides var. incisa, Turnera sidoides var. lycopifolia, Turnera simulans, Turnera Turnera stachydifolia var.
- a preferred genus is the plants of the genus Turnera diffusa WILLD, in particular Turnera diffusa var. Aphrodisiaca Urb. In particular, leaves or herbs are suitable as plant parts which are typically used in a cut or ground form for plant extraction.
- the extractants used are aqueous solutions of water-miscible organic solvents selected from ethanol, methanol, propanol, isopropanol, acetone and mixtures thereof.
- the extractant contains the solvent or solvent mixture in an amount of 20 to 90, preferably 30 to 80 and more preferably 50 to 70 wt .-%.
- the remainder of the extractant is water.
- the primary extraction is carried out exhaustively, while the extraction at elevated temperature, for example 30 to 50 0 C, preferably 40 to 50 0 C are performed.
- Multi-stage extractions can also be used.
- Amounts of 1 to 20 parts by weight, preferably 6 to 12 parts by weight of extractant have proven to be particularly suitable per part by weight of extractable plant parts.
- the extract obtained is concentrated to a thick extract. This can be done by methods known to the person skilled in the art, for example by evaporation in vacuo on a rotary evaporator, on a thin-film evaporator or on a plate evaporator.
- a key step in increasing the efficacy of the extract is a subsequent step of enrichment of lipophilic substances associated with the depletion of hydrophilic substances.
- the dispersion of the thick extract it has proven particularly suitable to select the amount of water such that about 2 to 12 parts by weight of the thickness extract are used per 100 parts by weight of water.
- Another method for enriching the lipophilic substances in the concentrate and thus for depleting the hydrophilic substances is a liquid / liquid extraction, with which a distribution of the ingredients between water and a non-water-soluble, lipophilic solvent is achieved.
- the aqueous phase is discarded and the lipophilic liquid extract continues to be used.
- Enrichment of lipophilic extracts can also be achieved by chromatographic methods in which lipophilic components, for example, are bound to RP materials and the unbound substances are removed before the bound substances are eluted.
- the above-described method of dispersing the thickness extract in water is particularly preferable.
- the preferred embodiment of dispersing produces an extracitric precipitate that is reextracted in an aqueous solution with an organic solvent of from 30 to 90 weight percent selected from methanol, ethanol, propanol, isopropanol, acetone, and mixtures thereof.
- organic solvent selected from 30 to 90 weight percent selected from methanol, ethanol, propanol, isopropanol, acetone, and mixtures thereof.
- the extractives available hereinafter are separated from the undissolved constituents and added to a spissum extract.
- dry excipients are preferably added and the resulting mixture dried.
- dry extracts are obtained which are easy to process.
- drying auxiliaries in particular those of polysaccharides such as gum arabic, xanthan gum, etc. and dry adjuvants based on crystalline cellulose and silicon dioxide have proven to be suitable.
- 0.1 to 0.6 parts by weight of gum arabic, 0.05 to 0.5 parts by weight of microcrystalline cellulose and 0.01 to 0.1 parts by weight of silica are used as dry auxiliaries per part by weight of the crude extract obtained.
- the invention also provides the extract obtainable by the process according to the invention, in particular in the form of a dry extract. This shows a marked inhibition of human phosphodiesterase V.
- the IC 50 value is preferably from 4 to 10 ⁇ g / ml according to the method described in the examples.
- the invention furthermore relates to the use of the extract according to the invention for the preparation of a preparation, in particular a medicament for the treatment of conditions in which an increase in the cellular cGMP level is desired by a delayed degradation of cGMP.
- the extract is therefore particularly suitable for the production of a preparation, in particular a medicament for the treatment of erectile dysfunctions, in particular insofar as the erectile dysfunction is caused by an organ-selective deficiency of cGMP.
- FIG. 1 shows the PDE-V inhibition of the extracts according to the invention in comparison to sildenafil according to Example 5.
- Figure Ia shows the PDE-V inhibition of sildenafil control.
- FIG. 1 b shows the PDE-V inhibition of the Damiana spissum extract according to the invention without drying auxiliaries [extract pattern 5-1].
- FIG. 1c shows the PDE-V inhibition of the Damiana dry extract according to the invention [extract pattern 5-2]
- extract pattern 5-2 the same amounts of native dry extract equivalent were used for the PDE-V test, so they are directly comparable.
- FIG. 2 shows schematically the preparation according to Example 3.
- FIG. 3 and FIG. 4 show thin-layer chromatographic analyzes of extracts.
- test system was characterized as follows - PDE-V assay
- the reaction was started by adding the substrate [ 3 H] -CGMP Tracer (0.003 ⁇ Ci / ⁇ l). Subsequently, the assay mixture was incubated at 30 0 C for 20 min. Zero controls t (0) were performed without addition of enzyme.
- IC 50 values were determined using a Tritium Scintillation Proximity Assay (PDE- [ 3 H] -CGMP SPA Amersham Biosciences TRKQ 7100) according to the instructions of the manufacturer Amersham. The measured values for the samples were determined from at least two experiments per concentration.
- Example 4 Dry Materials
- the liquid extract thus obtained can, however, neither be concentrated to a homogeneous spissum extract by a routine method, nor dried to a powder, since a large number of lipophilic substances, e.g. Chlorophyll is extracted, which is known to lead to precipitation and phase separations in spissum extracts. Only the transfer into a dry extract and its grinding can lead to a homogeneous product. However, the influence of various drying auxiliaries was surprising.
- the precipitated extractant precipitate was separated from the supernatant and then reextracted with ethanol 50% m / m in the ratio 1: 4. Insolubles were separated and discarded.
- the extractives thus obtained are clarified by filtration and evaporated to an ethanolic-aqueous liquid extract.
- the resulting liquid extract was mixed with the drying auxiliaries in dissolved or suspended form, homogenized and then evaporated solvent-free and dried under vacuum at 50 0 C.
- Confluent extract 70% Native / 70% Native / 70% Native / 70% Native use without auxiliary 25% GA / 25% GA / 25% MD / 25% PVPP / Damiana fabrics 5% PVP 5% Prosolv TM 5% Prosolv TM 5% Prosolv TM
- the test in the pharmacological test system shows that a special extract can be produced by the process steps and process parameters according to the invention, which is obtained by a multiple extraction compared to conventional extracts. increased activity against the phosphodiesterase V distinguished.
- the invention additionally enables the conversion of the obtained liquid extract into a storage-stabilized dry extract.
- the resulting liquid extract was added proportionally with the drying aids gum arabic (25%) and Prosolv TM (5%) in dissolved or suspended form, homogenized and solvent-free and dried under vacuum at 50 0 C (extract pattern 5-2).
- Extract pattern 5-1 8 ⁇ g / mL
- Extract pattern 5-2 5 ⁇ g / mL
- a comparative extract according to Arletti et al. produced. For this, leaves were macerated with ethanol 30% (v / v) at room temperature overnight. The extractant was separated and the residue was squeezed out. The squeezed liquid was combined with the extract. It was concentrated to a dry extract and redissolved to a fluid extract (1: 1).
- FIG. 3 shows a chromatographic examination for hydroquinone derivatives (silica gel 60 F 254 , anhydrous formic acid: water: ethyl acetate (6: 6: 88, v / v / v)) after evaporation with ammonia solution.
- Lane 1 shows the extract of Arletti, lane 3 the extract according to the invention.
- the extract according to Example 6 (Arletti) and the extract according to the invention were tested in concentrations of 1, 3, 10, 30 and 60 ⁇ g / ml in a PDE-5 assay.
- PDE-5 protein content 13.5 ⁇ g / ml
- 3 H-GMP 0.003 ⁇ Ci / ⁇ l
- the assay mixture was incubated at 30 ° C. for 20 min. Zero controls were performed without addition of PDE-V.
- the IC 50 - Values were determined using a Tricium Scintillation Proximity Assay (PDE [ 3 H] -CGMP; Amersham Biosciences TRKQ 7100) according to the manufacturer's instructions.
- the measured values for the samples were determined from two experiments and are given as mean values with respective deviations from the mean value.
- the dose-dependent reduction in enzyme activity under the effect of the particular sample or reference substance is expressed in a percentage dose-response curve.
- the IC 5 o values (sample concentration which causes a 50% inhibition of the maximum enzyme activity) were determined using the program GraphPad- Prism (version 4, GraphPad Software Inc., San Diego, CA, USA).
- Extract of the invention IC 50 2.5 ⁇ g / ml (95% confidence interval 2.13 to 2.86 ⁇ g / ml).
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gynecology & Obstetrics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BRPI0720292-0A BRPI0720292A2 (pt) | 2006-12-11 | 2007-12-11 | Extrato especial e uso do mesmo para inibição da degradação de monofosfato de guanosina cíclica (cgmp) |
US12/518,735 US8329228B2 (en) | 2006-12-11 | 2007-12-11 | Special extract and use thereof for inhibiting the degradation of cyclic guanosine monophosphate (cGMP) |
EP07857364.9A EP2094285B1 (de) | 2006-12-11 | 2007-12-11 | Spezialextrakt und seine verwendung zur hemmung des abbaus von cyclischem guanosinmonophosphat (cgmp) |
CA002672012A CA2672012A1 (en) | 2006-12-11 | 2007-12-11 | Special extract and use thereof for inhibiting the degradation of cyclic guanosine monophosphate (cgmp) |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06125821.6 | 2006-12-11 | ||
EP06125821A EP1932531A1 (de) | 2006-12-11 | 2006-12-11 | Spezialextrakt und seine Verwendung zur Hemmung des Abbaus von cyclischem Guanosinmonophosphat (cGMP) |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008071684A2 true WO2008071684A2 (de) | 2008-06-19 |
WO2008071684A3 WO2008071684A3 (de) | 2008-08-21 |
Family
ID=38121795
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2007/063668 WO2008071684A2 (de) | 2006-12-11 | 2007-12-11 | Spezialextrakt und seine verwendung zur hemmung des abbaus von cyclischem guanosinmonophosphat (cgmp) |
Country Status (5)
Country | Link |
---|---|
US (1) | US8329228B2 (de) |
EP (2) | EP1932531A1 (de) |
BR (1) | BRPI0720292A2 (de) |
CA (1) | CA2672012A1 (de) |
WO (1) | WO2008071684A2 (de) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT201900009018A1 (it) * | 2019-06-14 | 2020-12-14 | Carmen Iannella | Bevanda alcolica |
FR3122990A1 (fr) * | 2021-05-20 | 2022-11-25 | Patrinove | Extrait de vegetal a metabolisme acide crassulacéen pour utilisation dans le traitement des dysfonctionnements érectiles |
FR3122991A1 (fr) | 2021-05-20 | 2022-11-25 | Patrinove | Extrait de vegetal a metabolisme acide crassulaceen pour utilisation dans le traitement de la dysmenorrhee et/ou des douleurs liees aux spasmes et crampes menstruels |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003094943A1 (en) * | 2002-05-10 | 2003-11-20 | Indena S.P.A. | Formulations useful in the treatment of male and female impotence |
-
2006
- 2006-12-11 EP EP06125821A patent/EP1932531A1/de not_active Withdrawn
-
2007
- 2007-12-11 US US12/518,735 patent/US8329228B2/en active Active
- 2007-12-11 EP EP07857364.9A patent/EP2094285B1/de active Active
- 2007-12-11 CA CA002672012A patent/CA2672012A1/en not_active Abandoned
- 2007-12-11 BR BRPI0720292-0A patent/BRPI0720292A2/pt not_active Application Discontinuation
- 2007-12-11 WO PCT/EP2007/063668 patent/WO2008071684A2/de active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003094943A1 (en) * | 2002-05-10 | 2003-11-20 | Indena S.P.A. | Formulations useful in the treatment of male and female impotence |
Non-Patent Citations (4)
Title |
---|
ALARCON-AGUILAR F J ET AL: "INVESTIGATION ON THE HYPOGLYCAEMIC EFFECTS OF EXTRACTS OF FOUR MEXICAN MEDICINAL PLANTS IN NORMAL AND ALLOXAN-DIABETIC MICE" PHYTOTHERAPY RESEARCH, JOHN WILEY & SONS LTD. CHICHESTER, GB, Bd. 16, Nr. 4, Juni 2002 (2002-06), Seiten 383-386, XP008080184 ISSN: 0951-418X * |
ANTONIO M A ET AL: "Oral anti-inflammatory and anti-ulcerogenic activities of a hydroalcoholic extract and partitioned fractions of Turnera ulmifolia (Turneraceae)" JOURNAL OF ETHNOPHARMACOLOGY, Bd. 61, Nr. 3, Juli 1998 (1998-07), Seiten 215-228, XP002439812 ISSN: 0378-8741 * |
ARLETTI R ET AL: "Stimulating property of Turnera diffusa and Pfaffia paniculata extracts on the sexual behavior of male rats" PSYCHOPHARMACOLOGY, Bd. 143, Nr. 1, März 1999 (1999-03), Seiten 15-19, XP002438020 ISSN: 0033-3158 in der Anmeldung erwähnt * |
THARAKAN BINU ET AL: "Botanical therapies in sexual dysfunction" PHYTOTHERAPY RESEARCH, Bd. 19, Nr. 6, Juni 2005 (2005-06), Seiten 457-463, XP002438019 ISSN: 0951-418X in der Anmeldung erwähnt * |
Also Published As
Publication number | Publication date |
---|---|
EP2094285B1 (de) | 2015-07-08 |
EP1932531A1 (de) | 2008-06-18 |
WO2008071684A3 (de) | 2008-08-21 |
BRPI0720292A2 (pt) | 2014-02-04 |
EP2094285A2 (de) | 2009-09-02 |
US8329228B2 (en) | 2012-12-11 |
CA2672012A1 (en) | 2008-06-19 |
US20100119627A1 (en) | 2010-05-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0599307B1 (de) | Johanniskraut-Trockenextrakt, Verfahren zu seiner Herstellung und seine Verwendung | |
EP0692257B1 (de) | Verfahren zur Herstellung von pestizidarmen Wirkstoffkonzentraten aus Pflanzen | |
DE10164893B4 (de) | Verfahren zur Herstellung von Artischockenblätterextrakten und so erhaltene Artischockenblätterextrakte | |
DE3022281C2 (de) | Von Alkaloiden befreiter wäßriger Extrakt aus Aconitwurzeln und diesen Extrakt als Wirkstoff enthaltende pharmazeutische Zusammensetzung | |
EP2567703A2 (de) | Neuer Mariendistelextrakt, Verfahren zur Herstellung und Verwendung | |
EP2066333B1 (de) | Baldrian-extraktzubereitung | |
EP2320922B1 (de) | Kombination von extrakten aus verschiedenen pflanzen zur verbesserung der symptome von demenzerkrankungen | |
EP2182966B1 (de) | Verwendung von extrakten oder extraktivstoffen aus piper cubeba l. als wirksame bestandteile in einem medikament zur behandlung von krebserkrankungen | |
DE3511609C2 (de) | ||
EP2094285B1 (de) | Spezialextrakt und seine verwendung zur hemmung des abbaus von cyclischem guanosinmonophosphat (cgmp) | |
EP2069334B1 (de) | Aspalathin-ähnliches dihydrochalcon, extrakte aus unfermentiertem rotbusch und verfahren zur herstellung | |
CH650931A5 (de) | Extrakt von zedrach borken mit geschwulsthemmender wirkung und verfahren zu dessen herstellung. | |
WO2007054269A2 (de) | Extrakte aus der rinde von corynanthe-arten und deren verwendung sowie diese extrakte enthaltende arzneimittel, diätetische lebensmittel und pharmazeutische zubereitungen | |
AT400673B (de) | Verfahren für die herstellung von heilpflanzenextrakten | |
DE69915290T2 (de) | Verfahren zur extraktion eines bestandteiles von pflanzenmaterial | |
DE102005060880B4 (de) | Spezialextrakt zur Verwendung als Antiarrhytmikum bei Herzrhythmusstörungen und zur Verbesserung der Koronarperfusion sowie dessen Herstellung | |
DE60133138T2 (de) | (-)-olivil als antioxidationsmittel | |
DE2135492C3 (de) | Gewinnung eines Anacardhim occidentale L-Rindenextraktes mit antihypertensiver Wirkung | |
DE60133669T2 (de) | Zusammensetzungen zur auslösung der sekretion des insulinähnlichen wachstumsfaktors 1 | |
WO2020099595A1 (de) | Verwendung von extrakten aus den blättern der zitronenverbene (aloysia citriodora) zur steigerung der neuronalen, cerebralen verfügbarkeit von neurotransmittern, ausgewählt aus der gruppe serotonin, dopamin, noradrenalin | |
EP3763226A1 (de) | Zusammensetzung zur verminderung von haarausfall und zur verbesserung des haarwuchses bei androgenetischer alopezie | |
WO2009037225A2 (de) | Herstellung von blattextrakten von pittosporum phillyraeoides und deren verwendung in der medizin | |
WO2008009151A1 (de) | Tanninfreier trockenextrakt aus rhodiola rosea l. | |
DE102009040381A1 (de) | Verfahren zur Isolierung von Alkaloiden aus Pflanzen | |
DE3546505A1 (de) | Verwendung von caesalpinia-inhaltsstoffen zur vorbeugung der mikroangiopathie |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07857364 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2672012 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007857364 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12518735 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: PI0720292 Country of ref document: BR Kind code of ref document: A2 Effective date: 20090612 |